Steven J Altschuler
Overview
Explore the profile of Steven J Altschuler including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
64
Citations
4090
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sun X, Kumbier K, Gayathri S, Steri V, Wu L, Altschuler S
Cancer Res Commun
. 2024 Dec;
5(1):119-127.
PMID: 39699269
Eliminating "persisters" before relapse is crucial for achieving durable treatment efficacy. This study provides a rationale for developing PRMT1-selective inhibitors to target cancer persisters and achieve more durable outcomes in...
2.
Sun X, Wu L, Altschuler S, Hata A
Nat Cancer
. 2024 Sep;
5(9):1298-1304.
PMID: 39289594
Disease relapse driven by acquired drug resistance limits the effectiveness of most systemic anti-cancer agents. Targeting persistent cancer cells in residual disease before relapse has emerged as a potential strategy...
3.
Small molecule in situ resin capture provides a compound first approach to natural product discovery
Bogdanov A, Salib M, Chase A, Hammerlindl H, Muskat M, Luedtke S, et al.
Nat Commun
. 2024 Jun;
15(1):5230.
PMID: 38898025
Culture-based microbial natural product discovery strategies fail to realize the extraordinary biosynthetic potential detected across earth's microbiomes. Here we introduce Small Molecule In situ Resin Capture (SMIRC), a culture-independent method...
4.
Kumbier K, Roth M, Li Z, Lazzari-Dean J, Waters C, Hammerlindl S, et al.
Dev Cell
. 2024 Jun;
59(16):2134-2142.e6.
PMID: 38878774
Amyotrophic lateral sclerosis (ALS) is a rapidly progressing, highly heterogeneous neurodegenerative disease, underscoring the importance of obtaining information to personalize clinical decisions quickly after diagnosis. Here, we investigated whether ALS-relevant...
5.
A PINK1 input threshold arises from positive feedback in the PINK1/Parkin mitophagy decision circuit
Waters C, Angenent S, Altschuler S, Wu L
Cell Rep
. 2023 Oct;
42(10):113260.
PMID: 37851575
Mechanisms that prevent accidental activation of the PINK1/Parkin mitophagy circuit on healthy mitochondria are poorly understood. On the surface of damaged mitochondria, PINK1 accumulates and acts as the input signal...
6.
Li L, Shen S, Bickler P, Jacobson M, Wu L, Altschuler S
Elife
. 2023 Jul;
12.
PMID: 37494095
The ability to sense and respond to changes in cellular oxygen levels is critical for aerobic organisms and requires a molecular oxygen sensor. The prototypical sensor is the oxygen-dependent enzyme...
7.
Bogdanov A, Salib M, Chase A, Hammerlindl H, Muskat M, Luedtke S, et al.
bioRxiv
. 2023 Jul;
PMID: 37398257
Microbial natural products remain an important resource for drug discovery. Yet, commonly employed discovery techniques are plagued by the rediscovery of known compounds, the relatively few microbes that can be...
8.
Rinaldi C, Waters C, Li Z, Kumbier K, Rao L, Nichols R, et al.
Cell Rep
. 2023 May;
42(5):112447.
PMID: 37141099
Parkinson's disease-causing leucine-rich repeat kinase 2 (LRRK2) mutations lead to varying degrees of Rab GTPase hyperphosphorylation. Puzzlingly, LRRK2 GTPase-inactivating mutations-which do not affect intrinsic kinase activity-lead to higher levels of...
9.
Heinrich L, Kumbier K, Li L, Altschuler S, Wu L
ACS Chem Biol
. 2023 Mar;
18(4):679-685.
PMID: 36920184
High-content microscopy offers a scalable approach to screen against multiple targets in a single pass. Prior work has focused on methods to select "optimal" cellular readouts in microscopy screens. However,...
10.
Stolzel F, Fordham S, Nandana D, Lin W, Blair H, Elstob C, et al.
JCI Insight
. 2022 Dec;
8(2).
PMID: 36480300
Precision medicine can significantly improve outcomes for patients with cancer, but implementation requires comprehensive characterization of tumor cells to identify therapeutically exploitable vulnerabilities. Here, we describe somatic biallelic TET2 mutations...